

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – November 12, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. October 8, 2014 DUR Minutes – Vote

B. October 8, 2014 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Action Item – Vote on 2015 Meeting Dates – See Appendix B

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Update on Medication Coverage Authorization Unit/Oral Viscous Lidocaine Claims Analysis/Glaucoma Member and Prescriber Mailing Evaluation – See Appendix C

A. Medication Coverage Activity for October 2014

B. Pharmacy Help Desk Activity for October 2014

C. Oral Viscous Lidocaine Claims Analysis

D. Glaucoma Educational Initiative Mailing Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Otezla® (Apremilast) and Entyvio™ (Vedolizumab) – See Appendix D

A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Sivextro™ (Tedizolid), Dalvance™ (Dalbavancin), and Orbactiv™ (Oritavancin) – See Appendix E

A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Fetzima® (Levomilnacipran), Khedezla® (Desvenlafaxine), and Brintellix® (Vortioxetine) and Update the Antidepressants Product Based Prior Authorization Category – See Appendix F

A. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

9. 30-Day Notice to Prior Authorize Harvoni® (Ledipasvir/Sofosbuvir) – See Appendix G

- A. Introduction
- B. Market News and Updates
- C. Harvoni® (Ledipasvir/Sofosbuvir) Summary
- D. COP Recommendations
- E. Utilization of Sovaldi™ (Sofosbuvir) and Olysio™ (Simeprevir)
- F. Prior Authorization of Sovaldi™ (Sofosbuvir) and Olysio™ (Simeprevir)
- G. Utilization Details of Hepatitis C Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Action Item – Annual Review of Fibromyalgia Medications – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Fibromyalgia Medications
- C. Prior Authorization of Fibromyalgia Medications
- D. Market News and Updates
- E. COP Recommendations
- F. Utilization Details of Fibromyalgia Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

11. Annual Review of Oral Buprenorphine Products and 30-Day Notice to Prior Authorize Zubsolv® (Buprenorphine/Naloxone Tablets) and Bunavail™ (Buprenorphine/Naloxone Buccal Films) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Key Points
- C. Utilization of Oral Buprenorphine Products
- D. Prior Authorization of Oral Buprenorphine Products
- E. Market News and Updates
- F. Zubsolv® and Bunavail™ Summary
- G. COP Recommendations
- H. Utilization Details of Oral Buprenorphine Products

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

12. FDA and DEA Updates – See Appendix J

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

13. Future Business

- A. Annual Reviews
- B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

14. Adjournment